Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 39, Issue 1, pp 60–67 | Cite as

Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study

  • Sixten SellengEmail author
  • Kathleen Selleng
  • Sigrun Friesecke
  • Matthias Gründling
  • Sven-Olaf Kuhn
  • Ricarda Raschke
  • Olivia J. Heidecke
  • Carsten Hinz
  • Gregor Hron
  • Theodore E. Warkentin
  • Andreas Greinacher
Article

Abstract

Data on the frequency of anti-platelet factor 4/heparin (PF4/H) antibodies and their association with outcomes in intensive care unit (ICU) patients are sparse. In this prospective, observational study we screened 320 consecutive surgical/medical ICU patients for anti-PF4/H antibodies by enzyme-immunoassay (EIA) for immunoglobulin (Ig)G/A/M separately and heparin-induced platelet activation assay (HIPA) at ICU admission (=baseline), day 6, and day 10. HIPA-positive patients were additionally tested by serotonin-release assay (SRA). Patients tested positive by day 10: for anti-PF4/H-IgG = 17.2 % and for anti-PF4/H-IgM = 42.1 %. Within the first 10 ICU days, platelet counts decreased to <100 Gpt/L in 27.8 % patients. However, only seven patients (2.2 %) experienced a drop in the platelet count ≥50 % beginning after the fourth ICU day. These included the only two patients (0.6 %; 95 % confidence interval 0.08–2.2 %) with heparin-induced thrombocytopenia (HIT). Only strong reactions in the HIPA were reproducible by SRA. This study confirms that testing for anti-PF4/H IgG antibodies should be restricted to ICU-patients who develop a platelet count decrease of >50 % that begins after day four of heparin treatment (which may have started before ICU admission). Among patients testing positive by IgG-specific EIA a functional platelet activation assay should be performed (regarding only strong reactions as positive).

Keywords

Heparin-induced thrombocytopenia Laboratory testing Platelet 4/heparin antibodies Critical care Intensive care 

Notes

Acknowledgments

This study was supported by the German Federal Ministry for Education and Research (ZIK-HIKE 03Z2CK1) and was performed within the Department of Cardiovascular Medicine at the Medical Faculty, Ernst-Moritz-Arndt-Universität, Greifswald.

Conflict of interests

All authors state that they have no conflict of interests.

References

  1. 1.
    Greinacher A, Selleng K (2010) Thrombocytopenia in the intensive care unit patient. Hematol Am Soc Hematol Educ Progr 2010:135–143CrossRefGoogle Scholar
  2. 2.
    Cook D, Meade M, Guyatt G et al (2011) Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 364:1305–1314PubMedCrossRefGoogle Scholar
  3. 3.
    Levine RL, Hergenroeder GW, Francis JL et al (2010) Heparin-platelet factor 4 antibodies in intensive care patients: an observational seroprevalence study. J Thromb Thrombolysis 30:142–148PubMedCrossRefGoogle Scholar
  4. 4.
    Greinacher A, Juhl D, Strobel U et al (2007) Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 5:1666–1673PubMedCrossRefGoogle Scholar
  5. 5.
    Warkentin TE, Sheppard JA, Moore JC et al (2005) Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 146:341–346PubMedCrossRefGoogle Scholar
  6. 6.
    Sheridan D, Carter CKelton JG (1986) A diagnostic test for heparin-induced thrombocytopenia. Blood 67:27–30PubMedGoogle Scholar
  7. 7.
    Greinacher A, Michels I, Kiefel V et al (1991) A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 66:734–736PubMedGoogle Scholar
  8. 8.
    Juhl D, Eichler P, Lubenow N et al (2006) Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 76:420–426PubMedCrossRefGoogle Scholar
  9. 9.
    Eichler P, Budde U, Haas S et al (1999) First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost 81:625–629PubMedGoogle Scholar
  10. 10.
    Warkentin TE, Sheppard JI, Moore JC et al (2008) Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 6:1304–1312PubMedCrossRefGoogle Scholar
  11. 11.
    Warkentin TE, Sheppard JA, Horsewood P et al (2000) Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96:1703–1708PubMedGoogle Scholar
  12. 12.
    Warkentin TE, Greinacher A, Gruel Y et al (2011) Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost 9:2498–2500PubMedCrossRefGoogle Scholar
  13. 13.
    Greinacher A, Ittermann T, Bagemuhl J et al (2010) Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. J Thromb Haemost 8:2025–2031PubMedCrossRefGoogle Scholar
  14. 14.
    Lo GK, Juhl D, Warkentin TE et al (2006) Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759–765PubMedCrossRefGoogle Scholar
  15. 15.
    Hui P, Cook DJ, Lim W et al (2011) The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. Chest 139:271–278PubMedCrossRefGoogle Scholar
  16. 16.
    Selleng S, Selleng K, Wollert HG et al (2008) Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. J Thromb Haemost 6:428–435PubMedCrossRefGoogle Scholar
  17. 17.
    Crowther M, Cook D, Guyatt G et al (2014) Heparin-induced thrombocytopenia in the critically ill: interpreting the 4Ts test in a randomized trial. J Crit Care 29(470):e7–e15PubMedGoogle Scholar
  18. 18.
    Bakchoul T, Zollner H, Greinacher A (2014) Current insights into the laboratory diagnosis of HIT. Int J Lab Hematol 36:296–305PubMedCrossRefGoogle Scholar
  19. 19.
    Althaus K, Hron G, Strobel U et al (2013) Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia. Thromb Res 131:e85–e90PubMedCrossRefGoogle Scholar
  20. 20.
    Bakchoul T, Giptner A, Bein G et al (2011) Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). Thromb Res 127:345–348PubMedCrossRefGoogle Scholar
  21. 21.
    Bakchoul T, Giptner A, Najaoui A et al (2009) Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 7:1260–1265PubMedCrossRefGoogle Scholar
  22. 22.
    Sachs UJ, Von Hesberg J, Santoso S et al (2011) Evaluation of a new nanoparticle-based lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT). Thromb Haemost 106:1197–1202PubMedCrossRefGoogle Scholar
  23. 23.
    Savi P, Chong BH, Greinacher A et al (2005) Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 105:139–144PubMedCrossRefGoogle Scholar
  24. 24.
    Warkentin TE, Hayward CP, Smith CA et al (1992) Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 120:371–379PubMedGoogle Scholar
  25. 25.
    Warkentin TE (2012) Heparin-induced thrombocytopenia in the ICU: a transatlantic perspective. Chest 142:815–816PubMedCrossRefGoogle Scholar
  26. 26.
    Trehel-Tursis V, Louvain-Quintard V, Zarrouki Y et al (2012) Clinical and biological features of patients suspected or confirmed to have heparin-induced thrombocytopenia in a cardiothoracic surgical ICU. Chest 142:837–844PubMedCrossRefGoogle Scholar
  27. 27.
    Greinacher A, Kohlmann T, Strobel U et al (2009) The temporal profile of the anti-PF4/heparin immune response. Blood 113:4970–4976PubMedCrossRefGoogle Scholar
  28. 28.
    Warkentin TE, Sheppard JA, Moore JC et al (2009) Studies of the immune response in heparin-induced thrombocytopenia. Blood 113:4963–4969PubMedCrossRefGoogle Scholar
  29. 29.
    Crowther MA, Cook DJ, Albert M et al (2010) The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care 25:287–293PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Sixten Selleng
    • 1
    Email author
  • Kathleen Selleng
    • 2
  • Sigrun Friesecke
    • 3
  • Matthias Gründling
    • 1
  • Sven-Olaf Kuhn
    • 1
  • Ricarda Raschke
    • 2
  • Olivia J. Heidecke
    • 2
  • Carsten Hinz
    • 2
  • Gregor Hron
    • 2
  • Theodore E. Warkentin
    • 4
  • Andreas Greinacher
    • 2
  1. 1.Department of Anaesthesiology and Intensive CareUniversity Medicine GreifswaldGreifswaldGermany
  2. 2.Institute for Immunology and Transfusion MedicineUniversity Medicine GreifswaldGreifswaldGermany
  3. 3.Department of Internal Medicine BUniversity Medicine GreifswaldGreifswaldGermany
  4. 4.Hamilton Regional Laboratory Medicine Program, Department of Pathology and Molecular Medicine, Hamilton General Hospital, Hamilton Health SciencesMcMaster UniversityHamiltonCanada

Personalised recommendations